Primary endpoints: EASI, visual analog scale (VAS), Insomnia Severity Index (ISI), Dermatology Life Quality Index (DLQI), and Patient-Oriented Eczema Measure (POEM) scores (62)Secondary endpoints: Serum IL-4/IL-13/TGF-β1, TEWL/FLG, safety (local/systemic adverse events). The gene discussed is IL4; the disease is insomnia.